Brainstorm Cell Therapeutics Inc. (BCLI) — 10-Q Filings

10-Q Filings (6)

• Brainstorm's Losses Narrow, But Nasdaq Delisting Raises Red Flags — Nov 14, 2025 Risk: high
  BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported a net loss of $2.106 million for the three months ended September 30, 2025, an improvement from a net loss of
• Brainstorm Delisted from Nasdaq, Losses Mount Amid R&D Push — Aug 14, 2025 Risk: high
  BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported a net loss of $2.903 million for the three months ended June 30, 2025, compared to a net loss of $2.541 millio
• Brainstorm Cell Therapeutics Q1 2025 Financials Released — May 15, 2025 Risk: medium
  Brainstorm Cell Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $7.9 million and total liabilities o
• Brainstorm Cell Therapeutics Q3 2024 Update — Nov 14, 2024 Risk: high
  Brainstorm Cell Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $26.8 million and total liabilit
• Brainstorm Cell Therapeutics Q2 2024 Financial Update — Aug 14, 2024 Risk: medium
  Brainstorm Cell Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $79.6 million and total liabilities o
• BRAINSTORM CELL THERAPEUTICS INC. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: low
  BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Filing is a 10-Q for the period ending March 31, 2024. Co

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX